15 August 2013 - Deborah Wilkes
Archived
Valeant Pharmaceuticals International is exploring both tuck-in acquisitions and a merger of equals following its US$8.7 billion purchase of global eye health specialist Bausch + Lomb.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.